Approved indications: Haloperidol decanoate intramuscular injection is approved for maintenance treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy and have been previously stabilized on antipsychotic medication, typically oral haloperidol.

Common off-label uses: Clinicians may use haloperidol decanoate off label for related chronic psychotic disorders such as schizoaffective disorder or other psychoses in patients with poor adherence to oral antipsychotics, and occasionally for maintenance treatment in bipolar disorder with psychotic features; supporting evidence comes mainly from observational studies and extrapolation from oral haloperidol and other long‑acting injectable antipsychotics rather than large randomized trials.

Efficacy expectations: Symptom control usually begins to stabilize over the first 1–2 injections, with many patients showing meaningful improvement within 2–4 weeks, especially if they continue oral haloperidol briefly during the transition; in maintenance use, haloperidol decanoate reduces relapse and hospitalization risk in schizophrenia to a similar extent as oral haloperidol when equivalent doses are used.

Comparison to similar drugs: Compared with second‑generation long‑acting injectables, haloperidol decanoate has similar antipsychotic efficacy for positive symptoms but tends to cause more movement‑related side effects and prolactin elevation, while generally causing less weight gain, diabetes, and lipid problems.

How it is given: Haloperidol decanoate is administered only by a healthcare professional as a deep intramuscular injection, usually into the gluteal (buttock) muscle, once every 4 weeks (about monthly); it must never be given intravenously.

Typical adult dosing: For adults already stabilized on oral haloperidol, the initial dose is usually 10–20 times the prior total daily oral haloperidol dose (in milligrams), not exceeding 100 mg in the first injection; if a higher calculated dose is needed, up to 100 mg is given first and the rest 3–7 days later.

Maintenance dosing: Ongoing monthly maintenance doses commonly range from about 50–200 mg every 4 weeks (roughly 10–15 times the prior daily oral dose), adjusted gradually based on symptom control and side effects, with limited experience above 450 mg per month.

Transition from oral therapy: When starting haloperidol decanoate, clinicians often continue oral haloperidol or another antipsychotic for a short period (for example 1–2 weeks) until adequate blood levels from the injection are reached, then taper to the lowest effective long‑acting dose.

Special dosing considerations: Elderly, debilitated patients or those on low oral doses usually start at the lower end of the conversion range, and people with liver impairment or significant cardiac risk factors may also require lower starting doses and more cautious titration.

Missed injections: If an injection is missed or delayed, the patient should contact the clinic as soon as possible; based on how much time has passed, the prescriber may adjust the timing or dose of the next injection and, if needed, briefly restart oral antipsychotic medication, but patients should not receive “extra” injections without medical direction.

Overdose: Receiving too large a dose (or injections too close together) can cause severe drowsiness, profound movement disorders, low or high blood pressure, serious heart rhythm problems, or coma; suspected overdose is a medical emergency that requires urgent evaluation, heart rhythm monitoring, and supportive care, and in the United States clinicians may contact a Poison Control Center for guidance.

Common side effects: Frequently reported effects include injection‑site pain or soreness, drowsiness, insomnia, restlessness or akathisia (feeling unable to sit still), muscle stiffness or tremor, slowed movements (parkinsonism), dry mouth, constipation, blurred vision, and sexual or menstrual changes from raised prolactin levels; these often begin within days to weeks after an injection and may range from mild to bothersome.

Serious or rare adverse effects: Important but less common risks include severe extrapyramidal reactions (such as acute dystonia with muscle spasms), tardive dyskinesia (involuntary movements that can become permanent), neuroleptic malignant syndrome (fever, severe rigidity, confusion, autonomic instability), marked QT‑interval prolongation or serious heart rhythm problems (including torsades de pointes and sudden death), significant blood pressure changes, seizures, severe allergic reactions (including to sesame oil), liver injury, and serious blood count changes; any signs of chest pain, fainting, fast or irregular heartbeat, high fever, severe muscle stiffness, confusion, difficulty breathing, new uncontrollable movements, or swelling of the face or throat require emergency medical attention.

Warnings and precautions: All antipsychotics, including haloperidol decanoate, increase mortality in elderly patients with dementia‑related psychosis, and this product is not approved for that use; caution is needed in people with heart disease, a history of abnormal heart rhythms or long QT, low potassium or magnesium, liver impairment, seizures, Parkinson’s disease, dementia with Lewy bodies, or a history of severe reaction to antipsychotics.

Pregnancy and breastfeeding: Use during pregnancy is generally reserved for situations where potential benefits outweigh risks, especially in the third trimester when newborns can develop withdrawal or movement symptoms after birth; because haloperidol is excreted in breast milk, breastfeeding is usually not recommended while receiving haloperidol decanoate injections.

Age considerations: Safety and effectiveness in children have not been established, and elderly patients are more sensitive to side effects such as movement disorders, sedation, orthostatic hypotension, and cardiac effects, so they typically require lower starting doses and closer monitoring.

Relative safety profile: Versus second‑generation long‑acting antipsychotics, haloperidol decanoate generally has higher risk of extrapyramidal symptoms and tardive dyskinesia but lower risk of metabolic complications such as major weight gain and diabetes; individual tolerability varies widely.

Side effect reporting and safety updates: Patients should promptly report side effects to their prescriber or pharmacist, and in the United States they or their clinicians can report serious or unexpected reactions to the FDA MedWatch program (online or by phone) and check FDA safety communications for updated warnings about haloperidol products.

Other prescription and over‑the‑counter drugs: Haloperidol decanoate can interact with many medicines, including other drugs that prolong the QT interval (such as some antiarrhythmics, certain antibiotics, antifungals, and other antipsychotics), leading to increased risk of serious heart rhythm problems; combining with other central nervous system depressants (benzodiazepines, opioids, sedating antihistamines, sleep medicines) can increase drowsiness, dizziness, and risk of falls.

Metabolism interactions: Medicines that strongly inhibit CYP3A4 or CYP2D6 (for example some azole antifungals, macrolide antibiotics, certain HIV drugs, and antidepressants like fluoxetine or paroxetine) may raise haloperidol levels and side‑effect risk, whereas enzyme inducers such as carbamazepine, phenytoin, rifampin, and St John’s wort may lower levels and reduce efficacy, sometimes requiring dose adjustment under specialist supervision.

Other specific interactions: Caution is needed with lithium due to rare but serious encephalopathic and neurotoxic reactions, with diuretics or other drugs that lower potassium or magnesium because they increase QT‑prolongation risk, and with dopamine agonists (like levodopa) because they can oppose each other’s effects.

Alcohol, supplements, and foods: Alcohol and cannabis can significantly increase sedation, dizziness, and judgment impairment and are best avoided; some herbal preparations (such as St John’s wort) can alter drug metabolism, so all supplements and over‑the‑counter products should be discussed with the prescriber, though no specific food restrictions (such as grapefruit avoidance) are routinely required.

Conditions requiring extra caution: Use is generally avoided or used with great caution in patients with Parkinson’s disease, dementia with Lewy bodies, severe heart disease, known long QT syndrome, uncontrolled electrolyte abnormalities, severe liver disease, or a past history of neuroleptic malignant syndrome or severe tardive dyskinesia with antipsychotics.

Monitoring needs: Depending on individual risk factors, clinicians may obtain baseline and periodic ECGs to monitor QT interval, check electrolytes (especially potassium and magnesium), and follow weight, fasting glucose, and lipids; patients are also monitored regularly for extrapyramidal symptoms and tardive dyskinesia, prolactin‑related problems, and, when indicated, blood counts and liver function tests.

Q: How often do I need a haloperidol decanoate injection?
A: Most people receive haloperidol decanoate as a deep intramuscular injection once every 4 weeks (about monthly), though the exact schedule may be adjusted slightly based on how long the effect lasts for you.

Q: How long does one injection last in my body?
A: After a single injection, haloperidol decanoate slowly releases medicine over several weeks, usually providing therapeutic levels for about a month, which is why it is used as a monthly maintenance treatment.

Q: Will I still need to take oral antipsychotic pills when I start the injection?
A: When haloperidol decanoate is first started, many prescribers keep you on oral haloperidol or another antipsychotic for a short time so that symptom control is maintained while the long‑acting injection reaches steady levels, then reduce to the lowest effective maintenance regimen.

Q: Does haloperidol decanoate cause weight gain?
A: Some people gain weight on haloperidol decanoate, but on average it tends to cause less weight gain and fewer metabolic problems than many second‑generation antipsychotics, while still requiring attention to diet, exercise, and periodic checks of weight, blood sugar, and cholesterol.

Q: Can I drink alcohol while receiving haloperidol decanoate?
A: Alcohol can strongly increase drowsiness, dizziness, and the risk of accidents or breathing problems when combined with haloperidol, so drinking is generally discouraged and should be specifically discussed with your clinician.

Q: What happens if I decide to stop the injections?
A: Because the medicine remains in your system for weeks, stopping injections does not cause sudden withdrawal but psychotic symptoms can gradually return; any change or discontinuation should be planned with your prescriber, who may adjust doses or switch you back to oral treatment while closely monitoring for relapse.

Storage: Vials of haloperidol decanoate should be stored at controlled room temperature (about 68–77°F / 20–25°C), protected from light, kept in their outer carton, and must not be refrigerated or frozen; they should be kept out of reach of children and never used if discolored or containing particles.

Handling: Because this is a clinic-administered intramuscular injection in an oil base, storage, handling, and preparation are normally managed by healthcare professionals rather than by patients at home.

Disposal: Any unused or expired vials or used sharps (needles and syringes) should be disposed of through healthcare facility procedures or community medication take‑back programs, and should not be thrown into household trash or flushed down the toilet.